Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL28108223 | 0.98 | GBA1 (0.57) | GBA1ALDH1A1MAPTSIGMAR1FUCA1 | |
| SCHEMBL1844987 | 0.89 | ALDH1A1 (0.56) | GBA1ALDH1A1MAPTSIGMAR1 | |
| SCHEMBL2433049 | 0.89 | ALDH1A1 (0.56) | GBA1ALDH1A1MAPTSIGMAR1 | |
| SCHEMBL2230942 | 0.87 | GBA1 (0.50) | GBA1ALDH1A1 | |
| Methane SCHEMBL6969354 | 0.87 | ALDH1A1 (0.54) | GBA1ALDH1A1MAPT | |
| SCHEMBL2763581 | 0.85 | GBA1 (0.53) | GBA1ALDH1A1MAPTSIGMAR1FUCA1 | |
| Methane SCHEMBL7288556 | 0.85 | GBA1 (0.49) | GBA1ALDH1A1 | |
| SCHEMBL5743634 | 0.81 | MAPT (0.58) | GBA1ALDH1A1MAPTSIGMAR1FUCA1 | |
| SCHEMBL2430189 | 0.81 | GBA1 (0.64) | GBA1ALDH1A1MAPTSIGMAR1FUCA1 | |
| SCHEMBL2885978 | 0.79 | SIGMAR1 (0.54) | GBA1SIGMAR1ACHECCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261945-A1 | Compounds Having Activity at Nk3 Receptor and Uses Thereof in Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1812398-A1 | COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE | SmithKline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006050992-A1 | COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261945-A1 | Compounds Having Activity at Nk3 Receptor and Uses Thereof in Medicine | CNR1, ACKR3, HCAR3 | GBA1 423/4885ALDH1A1 704/4885MAPT 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.